Evaluation of biochemical indices following administration of artemether, halofantrine and a combination of artemether and lumefantrine in guinea pigs

Journal of Applied Pharmaceutical Science

Volumn 2, Issue 10, 2012, Pages 054-059

  Aprioku, J S ^a   Obianime, A W ^a  

^a UNIVERSITY OF PORT HARCOURT   (Nigeria)

Author keywords

ACTs; Artemether lumefantrine; Biochemical; Halofantrine; Lumefantrine

Indexed keywords

EID: 84876042318     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: 10.7324/JAPS.2012.21011     Document Type: Article

References (41)

1. Adaramoye O.A., Osaimoje D.O., Akinsanya A.M., Nneji C.M.,.Fafunso M.A., Ademowo O.G. Antioxidant status and biochemical indices after acute administration of artemether, artemether-lumefantrine and halofantrine in rats. Basic Clin. Pharmacol. Toxicol. 2008; 102(4): 412-418.
2. Adjuik M., Babiker A., Garner P., Olliaro P., Taylor W., White N.J. International artemisinin study group. artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004; 363: 9-17.
3. Aprioku J.S., Obianime A.W. Structure-Activity-Relationship (SAR) of artemisinins on some biological systems in male guinea pigs. Insights Pharm. Sci. 2011; 1(1): 1-10.
4. Babson L.A., Greeley S.J., Coleman C.M., Phillips G.D. Phenolphthalein monophosphate as a substrate for serum alkaline phosphatase. Clin. Chem. 1966; 12: 482- 490.
5. Canadian Council On Animal Care guidelines. The care and use of farm animals in research, teaching and testing, (2009). http://www.ccac.ca.
6. Chu T.M., Lin M.F. PSA and acid phosphatase in the diagnosis of prostate cancer. J. Clin. Ligand Assay. 1998; 21: 24-34.
7. De Villiers K.A., Marques H.M., Egan T.J. The crystal structure of halofantrine-ferriprotoporphyrin IX and the mechanism of action of arylmethanol antimalarials. J. Inorg. Biochem. 2008; 102(8): 1660-1667.
8. Didia B.C., Gbigbi P.S., Dapper D.V. Preliminary study on the effect of halofantrine hydrochloride on the testes of mature wistar rats. J. Appl. Sci. Environ. Manage. 2002; 6(1): 45-48.
9. Fishman H.W., Davidson M.H. Determination of serum acid phosphatases method. Biochem. Analysis. 2006. 4: 257-284.
10. Fossati P., Prencipe L., Berti G. Use of 3,5-dichloro-2- hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin. Chem. 1980; 26(2): 227-231
11. Gregus Z., Madhu C., Klaassen C.D. Species variation in toxication and detoxication of acetaminophen in vivo: a comparative study of biliary and urinary excretion of acetaminophen metabolites. J. Pharmacol. Exp. Therap. 1988; 244: 91-99.
12. Henry R.J., Cannon D.C., Winkelman J.W. Clinical chemistry, principles and techniques, 2nd ed. Harper & Row, New York (1974).
13. Hooper D.C., Scott G.S., Zborek A., Mikheeva T., Kean R.B., Koprowski H., Spitsin S.V. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of MS. FASEB J. 2000; 14(5): 691-698.
14. Katzung, B.G. Basic and clinical pharmacology. 9th ed. Lange, United States (2004).
15. Khan M.A., Smego Jr. R.A., Razi S.T., Beg M.A. Emerging drug - resistance and guidelines for treatment of malaria. Medicine Today. 2006; 4(3): 81-87.
16. Knapp C.M., Constantinescu C.S., Tan J.H., McLean R., Cherryman G.R., Gottlob I. Serum uric acid levels in optic neuritis. Mult. Scler. 2004; 10(3): 278-280.
17. Lin M.F., Lee C.L., Wojcieszyn J.W., Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. Fundamental biochemical and immunological aspects of prostatic acid phosphatase. Prostate. 1980; 1: 415-425.
18. Mueller E.A., van Vugt M., Kirch W., Andriano K., Hunt P., de Palacios P.I. Efficacy and safety of the six-dose regimen of artemetherlumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. Acta Tropica. 2006; 100: 41-53.
19. Nankivell B.J. Creatinine clearance and the assessment of renal function. Aust. Prescriber. 2001; 24:15-17.
20. Nosten F., ter Kuile F.O., Luxemburger C., Woodrow C., Kyle D.E., Chongsuphajaisiddhi T., White N.J. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 1993; 341: 1054-1056.
21. Nosten F., White N.J. Artemisinin-Based Combination Treatment of Falciparum Malaria. Am. J. Trop. Med. Hyg. 2007; 77(6): 181-192.
22. Nwanjo H.U., Iroagba I.I., Natuanya I.N., Eze N.A. Antifertility activity of dihydroartemisinin in male albino rats. Intern. J. Endocrinol.. 2007; 4: 1-5.
23. Obi E., Orisakwe O.E., Asomugha L.A., Udemezue O.O. The hepatotoxic effect of halofantrine in guinea pigs. Ind. J. Pharm. 2004; 36(5): 303-305.
24. Obianime A.W., Aprioku J.S. Comparative study of Artesunate, ACTs and their combinants on the spermatic parameters of the male guinea-pig. Nig. J. Physiol. Sci. 2009; 24(1):1-6.
25. Olliaro P.L., Taylor W.R. Developing artemisinin-based drug combinations for the treatment of drug-resistant falciparum malaria: a review. J. Postgrad. Med. 2004; 50: 40-44.
26. Orisakwe O.E., Obi E., Udemezue O.O. Effect of halofantrin on testicular architecture and testosterone level in guinea pigs. Eur. Bull. Drug Res. 2003; 11: 105-109.
27. Perrone R., Madias N., Levy A. Serum creatinine as an index of renal function: New insights into old concepts. Clin. Chem. 1992; 38: 1933-1953.
28. Price R.N., Uhlemann A.C., van Vugt M., Brockman A., Hutagalung R., Nair S., Nash D., Singhasivanon P., Anderson T.J., Krishna S., White N.J., Nosten F. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 2006; 42: 1570-1577.
29. Robert A., Dechy-Cabaret O., Cazelles J., Meunier B. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Accounts of Chemical Research 2002; 35: 167-174.
30. Roeschlau P., Bernt E., Gruber W.J. Enzymatic determination of total cholesterol in serum. J. Clin. Chem. Clin. Biochem. 1974; 12(5): 226.
31. Sachs J., Malaney P. The economic and social burden of malaria. Nature. 2002; 415: 680 -685.
32. Sharma V. Therapeutic Drugs for Targeting Chloroquine Resistance in Malaria. Mini Rev. Med. Chem. 2005; 5(4): 337-351.
33. Tietz N.W., Pruden E.L., Siggard-Anderson O. Textbook of clinical chemistry. Saunders, Philadelphia. (1986).
34. Traynor J., Geddes C.C., Fox J.G. How to measure renal function in clinical practice. Brit. Med. J. 2006; 333: 733-737.
35. Turpeinen M., Ghiciuc C., Opritoui M., Tursas L., Pelkonen O., Pasanen M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative study in vitro. Xenobiotica. 2007; 37(12):1367-1377.
36. van Vugt M., Kirch W., Andriano K., Hunt P., de Palacios P.I.. Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. Acta Tropica. 2006; 100: 41-53.
37. Weatherbum M.W. Phenol-hypochlorite reaction for determination of ammonia. Anal. Chem. 1967; 39: 971.
38. Wetterauer U. Recommended biochemical parameters for routine semen analysis. Urol. Res. 1986; 14(5): 241-246.
39. Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 2000; 80: 1107-1213.
40. Yam L.T. Clinical significance of the human acid phosphatases: a review. Am. J. Med. 1974; 56: 604-616.
41. Yeung S., Pongtavornpinyo W., Hastings I.M., Mills A.J., White N.J. Antimalarial Drug Resistance, Artemisinin-Based combination therapy, and the contribution of modeling to elucidating policy choices. Am. J. Trop. Med. Hyg. 2004; 7(2): 179-186.